

Resource Summary Report

Generated by [NIF](#) on Aug 20, 2026

B16

RRID:CVCL_F936

Type: Cell Line

Proper Citation

RCB Cat# RCB1283, RRID:CVCL_F936

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_F936

Proper Citation: RCB Cat# RCB1283, RRID:CVCL_F936

Description: Cell line B16 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Male

Disease: Mouse melanoma

Defining Citation: [PMID:1109790](#), [PMID:4981070](#), [PMID:5513504](#), [PMID:6498800](#)

Comments: Miscellaneous: This line seems to be the B78 line described in PubMed=4981070 which itself seems to be derived from the HFH-18 line that itself originate from a B16 melanoma.

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: B16

Synonyms: B-16, B16 melanoma, B16 subline B78, B78

Cross References: CLO:CLO_0050752, EFO:EFO_0022766, CCRID:1101MOU-PUMC000215, CCRID:1101MOU-PUMC000324, CCRID:3101MOUTCM2, CCRID:5301MOU-KCB14029YJ, ChEMBL-Cells:ChEMBL3308454, ChEMBL-Targets:ChEMBL381, CLS:305154, JCRB:JCRB0202, KCB:KCB 2014029YJ, KCB:KCB 93030YJ, PubChem_Cell_line:CVCL_F936, RCB:RCB1283, TKG:TKG 0144, TOKU-E:3564, Wikidata:Q25112368

ID: CVCL_F936

Vendor: RCB

Catalog Number: RCB1283

Hierarchy: cvcl_gs32

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260816T001947+0000

Ratings and Alerts

No rating or validation information has been found for B16.

No alerts have been found for B16.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. *Materials today. Bio*, 37, 102924.

Yan X, et al. (2026) Activation of T Cell-Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy. *Cancer discovery*, 16(1), 155.

He L, et al. (2026) Oral Delivery of siSIRP β via Yeast-Derived β -Glucan Particles Enhances Macrophage-Mediated Antitumor Immunity by Blocking the CD47-SIRP β Axis. *Journal of advanced research*.

Li J, et al. (2026) Effects of Different Chemical Modifications on the Polysaccharide Structure, Antioxidant, and Whitening Activities of *Lavandula angustifolia* Mill. *Chemistry & biodiversity*, 23(4), e71183.

Qin J, et al. (2026) Electrode material and electrical delivery mode shape the mechanisms and efficacy of electrochemical tumor ablation. *Bioelectrochemistry (Amsterdam, Netherlands)*, 171, 109301.

Sun JW, et al. (2026) Synergistic Induction of Apoptosis by Apocytochrome C and Sodium Aescinate Is Mediated by Excessive Autophagy via the AKT-mTOR-TFEB Signaling Axis. *Cell biochemistry and function*, 44(4), e70214.

- Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20252.
- Wu Y, et al. (2026) Stress-Induced ADGRL4 Orchestrates Tumor Progression and Metastasis by Inhibiting YAP1 Signaling and Activating Angiogenesis. *Cancer research*, 86(11), 2743.
- Yan H, et al. (2026) Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy. *Journal of nanobiotechnology*, 24(1).
- Qin J, et al. (2026) Spatially programmed Fe and Pt electrode-driven electrochemistry reconditions the tumor microenvironment and sensitizes triple-negative breast cancer to PD-1 Blockade. *Frontiers in oncology*, 16, 1819923.
- Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia* (New York, N.Y.), 67, 101196.
- Wang F, et al. (2025) TSH Ligand-Based CAR-T Cell Effectively Eradicates TSHR-Positive Thyroid Cancer with Favorable Safety Profile. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e13243.
- Rubio RM, et al. (2025) The transcription factor Helios restrains the anti-tumor capacity of CD8+ T cells. *Cell reports*, 44(12), 116680.
- Li S, et al. (2025) Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. *Cancer immunology research*, 13(8), 1284.
- Hadjigeorgiou AG, et al. (2025) Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy. *Cancer research*, 85(16), 3139.
- Fournier C, et al. (2025) Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model. *EBioMedicine*, 112, 105543.
- Wei L, et al. (2025) Cancer cachexia-related monocytic myeloid-derived suppressor cells impair T-cell negative selection and predict immune-related adverse events. *Liver research* (Beijing, China), 9(4), 298.
- Huang X, et al. (2024) Neddylation signaling inactivation by tetracaine hydrochloride suppresses cell proliferation and alleviates vemurafenib-resistance of melanoma. *Cell biology and toxicology*, 40(1), 81.
- Hagiyama M, et al. (2024) Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1. *Journal of controlled release : official journal of the Controlled Release Society*, 371, 603.
- Nueraihemaiti M, et al. (2024) The Anti-Vitiligo Effects of Feshurin In Vitro from *Ferula samarcandica* and the Mechanism of Action. *Pharmaceuticals* (Basel, Switzerland), 17(9).